Here is Why Lantheus Holdings Inc (LNTH) Is Among the Best Medical AI Stocks to Invest In

Lantheus Holdings Inc (NASDAQ:LNTH) is among the best medical AI stocks to buy now. Lantheus Holdings Inc (NASDAQ:LNTH) shares have climbed roughly 23% year-to-date and soared more than 46% over the past six months.

Lantheus is expanding its product portfolio amid growing demand for medical imaging solutions. On March 6, the company announced FDA approval of its imaging agent PYLARIFY TruVu.

The company also awaits FDA approval for its diagnostic imaging kit called LNTH-2501. The FDA extended its review of LNTH-2501 by three months to allow it more time to look at the product’s manufacturing information. The FDA decision on the kit is expected by June 29.

Reacting to the FDA’s extended review of LNTH-2501, Citizens on March 18 reiterated its Market Outperform rating and $85.00 price target on Lantheus stock. Citizens notes that despite the extended review time, LNTH-2501 has the potential to be the only imaging kit of its kind with TPT reimbursement.

In Q4 2025, Lantheus’ revenue increased 4.0% YoY to $406.8 million. The company posted a net income of $54.1 million for the quarter, compared to a net loss of $11.8 million in the same period the prior year. Lantheus exited 2025 with $359.1 million in cash and $750.0 million in its revolving credit line.

Lantheus Holdings Inc (NASDAQ:LNTH), based in Massachusetts, is a radiopharmaceutical company. It makes imaging agents that help in detecting and managing serious diseases. Its product, called PYLARIFY is an imaging agent used for detecting prostate cancer. Its other product, called DEFINITY, is an ultrasound-enhancing agent used to improve imaging of the heart.

READ NEXT: David Abrams’ Hedge Fund Is Betting On These 8 Stocks and 10 Best Energy Storage Stocks to Buy According to Hedge Funds.

Disclosure: None. Follow Insider Monkey on Google News.